The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 24, 2018

Filed:

Jan. 23, 2014
Applicant:

Kuros Biosciences Ag, Zürich-Schlieren, CH;

Inventors:

Martin F. Bachmann, Winterthur, CH;

Tazio Storni, Viganello, CH;

Patrik Maurer, Winterthur, CH;

Alain Tissot, Zürich, CH;

Katrin Schwarz, Schlieren, CH;

Edwin Meijerink, Zürich, CH;

Gerd Lipowsky, Zürich, CH;

Paul Pumpens, Riga, LV;

Indulis Cielens, Riga, LV;

Regina Renhofa, Riga, LV;

Assignee:

KUROS BIOSCIENCES AG, Schlieren, CH;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); C07K 14/005 (2006.01); A61K 39/02 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); A61K 39/00 (2013.01); A61K 39/0011 (2013.01); A61K 39/02 (2013.01); A61K 39/39 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/52 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/57 (2013.01); A61K 2039/6075 (2013.01); C07K 2319/00 (2013.01); C12N 2710/22022 (2013.01); C12N 2710/22023 (2013.01); C12N 2730/10122 (2013.01); C12N 2730/10123 (2013.01); C12N 2795/00034 (2013.01); C12N 2795/18122 (2013.01);
Abstract

The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.


Find Patent Forward Citations

Loading…